• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Intercept Pharmaceuticals - Articles and news items

Intercept’s new PBC liver disease treatment yields successful clinical trials

Industry news / 25 August 2016 / Intercept Pharmaceuticals

The trial evaluated safety and efficacy of ocaliva in PBC patients with an inadequate therapeutic response to, lack of tolerance to, ursodeoxycholic acid…

FDA approves Ocaliva for primary biliary cholangitis

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

The FDA has granted accelerated approval to Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis…

Intercept submits applications for marketing approval of obeticholic acid for the treatment of PBC

Industry news / 30 June 2015 / Victoria White

Intercept Pharmaceuticals has achieved two important regulatory milestones for obeticholic acid in primary biliary cirrhosis (PBC)…